Search Results - "Borchmann, Peter"

Entwicklungen in der Rezidivtherapie des diffusen großzelligen B-Zell-Lymphoms

Developments in the treatment of recurrent diffuse large B-cell lymphoma

von Tresckow, Bastian^{Aff1, IDs00761025017081_cor1}, Borchmann, Peter

Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group: LYMPHOMA

Eichenauer, Dennis A.^{Aff1, Aff2, IDs41375025026413_cor1}, Basaran, Aylin^{Aff1, Aff2}, Bühnen, Ina^{Aff1, Aff2}, Fuchs, Michael^{Aff1, Aff2}, von Tresckow, Bastian^{Aff2, Aff3}, Rosenwald, Andreas, Hansmann, Martin-Leo, Bernd, Heinz-Wolfram, Borchmann, Peter^{Aff1, Aff2}, Klapper, Wolfram, Hartmann, Sylvia

T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma: LYMPHOMA

Seifert, Nicole^Aff1, Reinke, Sarah^Aff2, Grund, Johanna, Müller-Meinhard, Berit, Richter, Julia, Heilmann, Thorsten, Schlößer, Hans, Kotrova, Michaela, Brüggemann, Monika, Borchmann, Peter^{Aff6, Aff7}, Bröckelmann, Paul J.^{Aff6, Aff7, Aff8}, Altenbuchinger, Michael, Klapper, Wolfram^{Aff2, IDs41375024024906_cor1}

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial

Fossa, Alexander, Molin, Daniel, 1969, Broeckelmann, Paul J., Schneider, Gundolf, Schnetzke, Ulf, Linderoth, Johan, Kamper, Peter M. H., Leppä, Sirpa M., Meissner, Julia, Schaub, Valdete, Lia, Kjersti, Fuchs, Michael, Borchmann, Peter, Böll, Boris

electronic

Non-Hodgkin-Lymphome: Therapiestrategien im Umbruch

Non-Hodgkin lymphoma: treatment strategies in transition

Borchmann, Peter^{Aff1, IDs00761025017152_cor1}, Oertel, Michael^{Aff2, IDs00761025017152_cor2}

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Borchmann, Peter, Ferdinandus, Justin, Schneider, Gundolf, Moccia, Alden, Greil, Richard, Hertzberg, Mark, Schaub, Valdete, Hüttmann, Andreas, Keil, Felix, Dierlamm, Judith, Hänel, Mathias, Novak, Urban, Meissner, Julia, Zimmermann, Andreas, Mathas, Stephan, Zijlstra, Josee M., Fossa, Alexander, Viardot, Andreas, Hertenstein, Bernd, Martin, Sonja, Giri, Pratyush, Scholl, Sebastian, Topp, Maxs, Jung, Wolfram, Vucinic, Vladan, Beck, Hans-Joachim, Kerkhoff, Andrea, Unger, Benjamin, Rank, Andreas, Schroers, Roland, Bueschenfelde, Christian Meyer zum, de Wit, Maike, Trautmann-Grill, Karolin, Kamper, Peter, Molin, Daniel, 1969, Kreissl, Stefanie, Kaul, Helen, von Tresckow, Bastian, Borchmann, Sven, Behringer, Karolin, Fuchs, Michael, Rosenwald, Andreas, Klapper, Wolfram, Eich, Hans-Theodor, Baues, Christian, Zomas, Athanasios, Hallek, Michael, Dietlein, Markus, Kobe, Carsten, Diehl, Volker

electronic

Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.

Eichenauer, Dennis A.^1,2 (AUTHOR) dennis.eichenauer@uk-koeln.de, Borchmann, Peter^1,2 (AUTHOR)

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Morschhauser, Franck^{Aff1, IDs41591024029869_cor1}, Dahiya, Saurabh^{Aff2, Aff3}, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, Nastoupil, Loretta J.

Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

Voltin, Conrad-Amadeus^{Aff1, IDs00259023065540_cor1}, Paccagnella, Andrea, Winkelmann, Michael, Heger, Jan-Michel^{Aff4, Aff5}, Casadei, Beatrice^{Aff2, Aff6}, Beckmann, Laura, Herrmann, Ken^{Aff7, Aff8}, Dekorsy, Franziska J., Kutsch, Nadine^{Aff4, Aff5}, Borchmann, Peter^{Aff4, Aff5}, Fanti, Stefano^{Aff2, Aff10}, Kunz, Wolfgang G., Subklewe, Marion^{Aff11, Aff12, Aff13}, Kobe, Carsten, Zinzani, Pier Luigi^{Aff2, Aff6}, Stelljes, Matthias, Roth, Katrin S., Drzezga, Alexander, Noppeney, Richard^{Aff8, Aff15}, Rahbar, Kambiz, Reinhardt, H. Christian^{Aff8, Aff15}, von Tresckow, Bastian^{Aff8, Aff15}, Seifert, Robert^{Aff7, Aff8, Aff16}, Albring, Jörn C., Blumenberg, Viktoria^{Aff11, Aff12, Aff13}, Farolfi, Andrea, Flossdorf, Sarah, Gödel, Philipp^{Aff4, Aff5}, Hanoun, Christine^{Aff8, Aff15}

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study

Santarsieri, Anna ^{a, b, c}, Mitchell, Emily ^{a, b, *}, Pham, My H ^{d, *}, Sanghvi, Rashesh ^{d, *}, Jablonski, Janina ^{e, f}, Lee-Six, Henry ^{d, g}, Sturgess, Katherine ^a, Brice, Pauline ^h, Menne, Tobias F ⁱ, Osborne, Wendy ^{i, j}, Creasey, Thomas ⁱ, Ardeshna, Kirit M ^k, Baxter, Joanna ^l, Behan, Sarah ^a, Bhuller, Kaljit ^m, Booth, Stephen ⁿ, Chavda, Nikesh D ^o, Collins, Graham P ^p, Culligan, Dominic J ^q, Cwynarski, Kate ^k, Davies, Andrew ^r, Downing, Abigail ^s, Dutton, David ^t, Furtado, Michelle ^u, Gallop-Evans, Eve ^s, Hodson, Andrew ^v, Hopkins, David ^w, Hsu, Hannah ^k, Iyengar, Sunil ^x, Jones, Stephen G ^y, Karanth, Mamatha ^z, Linton, Kim M ^aa, Lomas, Oliver C ^p, Martinez-Calle, Nicolas ^ab, Mathur, Abhinav ^q, McKay, Pamela ^w, Nagumantry, Sateesh K ^ac, Phillips, Elizabeth H ^aa, Phillips, Neil ^ad, Rudge, John F ^ae, Shah, Nimish K ^af, Stafford, Gwyneth ^a, Sternberg, Alex ^t, Trickey, Rachel ^s, Uttenthal, Benjamin J ^a, Wetherall, Natasha ^r, Zhang, Xiao-Yin ^p, McMillan, Andrew K ^ab, Coleman, Nicholas ^g, Stratton, Michael R ^d, Laurenti, Elisa ^b, Borchmann, Peter ^{e, f}, Borchmann, Sven ^{e, f}, Campbell, Peter J ^d, Rahbari, Raheleh ^{d, †, **}, Follows, George A ^{a, c, ag, †, *}

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma

Thurner, Lorenz, Fadle, Natalie, Regitz, Evi, Roth, Sophie, Cetin, Onur, Kos, Igor Age, Hess, Simon Mauro, Bein, Julia, Bohle, Rainer Maria, Vornanen, Martine, Sundström, Christer, de Leval, Laurence, Tiacci, Enrico, Borchmann, Peter, Engert, Andreas, Poeschel, Viola, Held, Gerhard, Schwarz, Eva C., Neumann, Frank, Preuss, Klaus -Dieter, Hoth, Markus, Kueppers, Ralf, Lehmann, Karola, Hansmann, Martin-Leo, Becker, Soeren L., Bewarder, Moritz, Hartmann, Sylvia

electronic

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Fuchs, Michael, Jacob, Anne Sophie, Kaul, Helen, Kobe, Carsten, Kuhnert, Georg, Pabst, Thomas^{Aff4, Aff5}, Greil, Richard^{Aff6, Aff7}, Bröckelmann, Paul J., Topp, Max S., Just, Marianne, Hertenstein, Bernd, Soekler, Martin, Vogelhuber, Martin, Zijlstra, Josée M., Keller, Ulrich Bernd, Krause, Stefan W., Dührsen, Ulrich, Meissner, Julia, Viardot, Andreas, Eich, Hans-Theodor, Baues, Christian, Diehl, Volker, Rosenwald, Andreas, Buehnen, Ina, von Tresckow, Bastian^{Aff1, Aff22}, Dietlein, Markus, Borchmann, Peter, Engert, Andreas, Eichenauer, Dennis A.^{Aff1, IDs4137502302064y_cor29}

Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group

Ferdinandus, Justin^{Aff1, Aff2, IDs0025902306431w_cor1}, van Heek, Lutz^{Aff2, Aff3}, Roth, Katrin^{Aff2, Aff3}, Dietlein, Markus^{Aff2, Aff3}, Eich, Hans-Theodor^{Aff2, Aff4}, Baues, Christian^{Aff2, Aff5, Aff6}, Borchmann, Peter^{Aff1, Aff2}, Kobe, Carsten^{Aff2, Aff3}

Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study

Esser, Peter^{Aff1, IDs10880023099446_cor1}, Müller, Horst, Borchmann, Peter, Kreissl, Stefanie, Knoop, Hans, Platzbecker, Uwe, Vucinic, Vladan, Mehnert-Theuerkauf, Anja

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Mackensen, Andreas^{Aff1, Aff2}, Haanen, John B.A.G.^{Aff3, Aff4}, Koenecke, Christian, Alsdorf, Winfried, Wagner-Drouet, Eva, Borchmann, Peter, Heudobler, Daniel^{Aff2, Aff9}, Ferstl, Barbara^{Aff1, Aff2}, Klobuch, Sebastian, Bokemeyer, Carsten, Desuki, Alexander, Lüke, Florian^{Aff2, Aff9}, Kutsch, Nadine, Müller, Fabian^{Aff1, Aff2}, Smit, Eveline, Hillemanns, Peter, Karagiannis, Panagiotis, Wiegert, Erol, He, Ying, Ho, Thang, Kang-Fortner, Qing, Schlitter, Anna Melissa, Schulz-Eying, Catrine, Finlayson, Andrew, Flemmig, Carina, Kühlcke, Klaus, Preußner, Liane, Rengstl, Benjamin^{Aff12, Aff15}, Türeci, Özlem^{Aff12, Aff13, Aff14, Aff15}, Şahin, Uğur^{Aff12, Aff13, Aff14, Aff15, IDs41591023026120_cor30}

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

Driessen, Julia, de Wit, Fer, Herrera, Alex F., Zinzani, Pier Luigi, LaCasce, Ann S., Cole, Peter D., Moskowitz, Craig H., García-Sanz, Ramón, Fuchs, Michael, Müller, Horst, Borchmann, Peter, Santoro, Armando, Schöder, Heiko, Zijlstra, Josée M., Hutten, Barbara A., Moskowitz, Alison J., Kersten, Marie José

High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial

Schorb, Elisabeth ^*, Isbell, Lisa Kristina, Kerkhoff, Andrea, Mathas, Stephan, Braulke, Friederike, Egerer, Gerlinde, Röth, Alexander, Schliffke, Simon, Borchmann, Peter, Brunnberg, Uta, Kroschinsky, Frank, Möhle, Robert, Rank, Andreas, Wellnitz, Dominique, Kasenda, Benjamin, Pospiech, Lisa, Wendler, Julia, Scherer, Florian, Deckert, Martina, Henkes, Elina, von Gottberg, Philipp, Gmehlin, Dennis, Backenstraß, Matthias, Jensch, Antje, Burger-Martin, Elvira, Grishina, Olga, Fricker, Heidi, Malenica, Natalie, Orbán, András, Duyster, Justus, Ihorst, Gabriele, Finke, Juergen, Illerhaus, Gerald

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Heger, Jan-Michel, Mattlener, Julia, Schneider, Jessica, Gödel, Philipp, Sieg, Noëlle, Ullrich, Fabian, Lewis, Richard, Bucaciuc-Mracica, Teodora, Schwarz, Roland F., Rueß, Daniel, Ruge, Maximilian I., Montesinos-Rongen, Manuel, Deckert, Martina, Blau, Tobias, Kutsch, Nadine, Balke-Want, Hyatt, Weiss, Jonathan, Becker, Kerstin, Reinhardt, H. Christian, Hallek, Michael, Borchmann, Peter, von Tresckow, Bastian, Borchmann, Sven

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Morschhauser, Franck^{Aff1, IDs41591024031754_cor1}, Dahiya, Saurabh^{Aff2, Aff3}, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, Nastoupil, Loretta J.

Erste S3-Leitlinie zum diffusen großzelligen B-Zell-Lymphom und zu verwandten Entitäten

First S3 guideline on diffuse large B-cell lymphoma and related entities

Ernst, Moritz, Skoetz, Nicole, Borchmann, Peter^{Aff1, IDs12312023012157_cor3}